 Christopher Raeburn
Concepts (369)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 15 | 2025 | 324 | 2.210 |
Why?
| | Neuroendocrine Tumors | 2 | 2022 | 108 | 0.850 |
Why?
| | Reoperation | 2 | 2024 | 587 | 0.770 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2024 | 1069 | 0.750 |
Why?
| | Thyroidectomy | 7 | 2024 | 96 | 0.700 |
Why?
| | Thyroid Carcinoma, Anaplastic | 4 | 2022 | 33 | 0.570 |
Why?
| | Pancreatic Neoplasms | 3 | 2022 | 859 | 0.560 |
Why?
| | Myocardial Ischemia | 3 | 2011 | 278 | 0.520 |
Why?
| | Heart | 4 | 2004 | 613 | 0.480 |
Why?
| | Intercellular Adhesion Molecule-1 | 5 | 2011 | 142 | 0.440 |
Why?
| | Lipopolysaccharides | 6 | 2002 | 889 | 0.430 |
Why?
| | Ischemic Preconditioning | 3 | 2004 | 50 | 0.430 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 3 | 2002 | 42 | 0.420 |
Why?
| | Tumor Necrosis Factor-alpha | 8 | 2010 | 1248 | 0.370 |
Why?
| | Diiodothyronines | 1 | 2011 | 2 | 0.360 |
Why?
| | Propionates | 1 | 2011 | 40 | 0.350 |
Why?
| | Neutrophils | 8 | 2011 | 1280 | 0.340 |
Why?
| | Myocarditis | 1 | 2011 | 100 | 0.320 |
Why?
| | Technetium Tc 99m Sestamibi | 3 | 2015 | 13 | 0.320 |
Why?
| | Parathyroid Glands | 3 | 2015 | 11 | 0.320 |
Why?
| | Ischemic Preconditioning, Myocardial | 4 | 2010 | 35 | 0.320 |
Why?
| | Medical Oncology | 2 | 2025 | 304 | 0.310 |
Why?
| | Myocardium | 6 | 2011 | 922 | 0.310 |
Why?
| | Delirium | 4 | 2014 | 96 | 0.310 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2021 | 222 | 0.310 |
Why?
| | Surgical Procedures, Operative | 2 | 2002 | 263 | 0.300 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 206 | 0.280 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2016 | 254 | 0.280 |
Why?
| | Receptors, Tumor Necrosis Factor | 3 | 2003 | 166 | 0.280 |
Why?
| | Shock, Hemorrhagic | 4 | 2004 | 170 | 0.270 |
Why?
| | Adrenocortical Carcinoma | 2 | 2018 | 63 | 0.270 |
Why?
| | Postoperative Complications | 9 | 2023 | 2738 | 0.250 |
Why?
| | Neck Dissection | 2 | 2024 | 18 | 0.250 |
Why?
| | Receptors, Cell Surface | 3 | 2004 | 394 | 0.250 |
Why?
| | Radionuclide Imaging | 3 | 2013 | 118 | 0.240 |
Why?
| | Biomarkers, Tumor | 5 | 2024 | 1237 | 0.240 |
Why?
| | Myocardial Infarction | 2 | 2011 | 1069 | 0.240 |
Why?
| | Antigens, CD | 3 | 2003 | 537 | 0.230 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2021 | 88 | 0.220 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2024 | 16 | 0.220 |
Why?
| | Thyroglobulin | 1 | 2024 | 27 | 0.220 |
Why?
| | Hypocalcemia | 2 | 2015 | 27 | 0.220 |
Why?
| | Iodine Radioisotopes | 4 | 2022 | 140 | 0.210 |
Why?
| | Carcinoma, Neuroendocrine | 3 | 2022 | 34 | 0.210 |
Why?
| | Lymph Node Excision | 1 | 2024 | 169 | 0.210 |
Why?
| | Drosophila Proteins | 2 | 2002 | 202 | 0.200 |
Why?
| | Thyroid Nodule | 1 | 2024 | 55 | 0.200 |
Why?
| | Endotoxemia | 2 | 2010 | 87 | 0.200 |
Why?
| | Osteitis Fibrosa Cystica | 1 | 2002 | 1 | 0.200 |
Why?
| | Hyperparathyroidism | 1 | 2002 | 11 | 0.200 |
Why?
| | Thyroxine | 1 | 2023 | 63 | 0.200 |
Why?
| | Humans | 49 | 2025 | 139073 | 0.200 |
Why?
| | Pheochromocytoma | 2 | 2021 | 57 | 0.190 |
Why?
| | Membrane Glycoproteins | 2 | 2002 | 500 | 0.190 |
Why?
| | Hypothyroidism | 1 | 2023 | 73 | 0.190 |
Why?
| | Iodine | 1 | 2022 | 26 | 0.190 |
Why?
| | Thoracic Surgery | 1 | 2004 | 139 | 0.190 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 108 | 0.190 |
Why?
| | Prognosis | 5 | 2024 | 4024 | 0.190 |
Why?
| | Adenocarcinoma | 2 | 2022 | 884 | 0.180 |
Why?
| | Chemokines | 4 | 2011 | 227 | 0.180 |
Why?
| | Compartment Syndromes | 1 | 2001 | 29 | 0.180 |
Why?
| | Interleukin-18 | 1 | 2002 | 236 | 0.170 |
Why?
| | Multiple Trauma | 1 | 2001 | 104 | 0.170 |
Why?
| | Abdomen | 1 | 2001 | 136 | 0.170 |
Why?
| | Adrenalectomy | 1 | 2000 | 65 | 0.170 |
Why?
| | Regeneration | 1 | 2002 | 198 | 0.170 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 150 | 0.170 |
Why?
| | Tryptophan | 2 | 2014 | 183 | 0.160 |
Why?
| | Paraganglioma | 1 | 2021 | 53 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 183 | 0.160 |
Why?
| | Middle Aged | 19 | 2024 | 33867 | 0.160 |
Why?
| | Aged | 15 | 2024 | 24237 | 0.150 |
Why?
| | Abdominal Injuries | 1 | 2000 | 122 | 0.150 |
Why?
| | Male | 29 | 2024 | 68330 | 0.150 |
Why?
| | Animals | 20 | 2021 | 37352 | 0.150 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 34 | 0.150 |
Why?
| | Mice, Inbred C57BL | 8 | 2011 | 5813 | 0.150 |
Why?
| | Trans-Activators | 1 | 2021 | 395 | 0.150 |
Why?
| | Stress, Physiological | 1 | 2002 | 454 | 0.140 |
Why?
| | Treatment Outcome | 6 | 2024 | 10965 | 0.140 |
Why?
| | Myocytes, Cardiac | 1 | 2002 | 510 | 0.140 |
Why?
| | Stem Cells | 1 | 2002 | 599 | 0.140 |
Why?
| | Adrenal Cortex | 1 | 2018 | 33 | 0.140 |
Why?
| | Pancreatectomy | 1 | 2000 | 244 | 0.140 |
Why?
| | Mice | 15 | 2021 | 17867 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 263 | 0.140 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 36 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1399 | 0.130 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2018 | 60 | 0.130 |
Why?
| | Carcinoma | 1 | 2018 | 230 | 0.130 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 4 | 2004 | 83 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1748 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 3 | 2021 | 914 | 0.120 |
Why?
| | Follow-Up Studies | 2 | 2024 | 5167 | 0.120 |
Why?
| | Cytokines | 2 | 2015 | 2084 | 0.120 |
Why?
| | Antibodies | 3 | 2002 | 408 | 0.120 |
Why?
| | Adrenal Glands | 1 | 2016 | 75 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 431 | 0.120 |
Why?
| | Virus Latency | 1 | 2016 | 79 | 0.120 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 96 | 0.120 |
Why?
| | Sepsis | 1 | 2001 | 610 | 0.110 |
Why?
| | Multimodal Imaging | 1 | 2015 | 117 | 0.110 |
Why?
| | Islets of Langerhans | 1 | 2000 | 793 | 0.110 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2014 | 50 | 0.110 |
Why?
| | Female | 19 | 2024 | 74078 | 0.110 |
Why?
| | Retrospective Studies | 6 | 2024 | 15924 | 0.110 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 206 | 0.110 |
Why?
| | DNA, Viral | 1 | 2016 | 369 | 0.100 |
Why?
| | Carotid Artery Injuries | 2 | 2004 | 39 | 0.100 |
Why?
| | Elective Surgical Procedures | 2 | 2014 | 192 | 0.100 |
Why?
| | Tunica Intima | 2 | 2004 | 76 | 0.100 |
Why?
| | Subtraction Technique | 1 | 2013 | 25 | 0.100 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2015 | 388 | 0.100 |
Why?
| | Preoperative Care | 3 | 2024 | 368 | 0.100 |
Why?
| | Mice, Knockout | 7 | 2004 | 3038 | 0.100 |
Why?
| | Chemokine CCL2 | 2 | 2011 | 116 | 0.100 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2015 | 755 | 0.100 |
Why?
| | Herpesvirus 3, Human | 1 | 2016 | 331 | 0.090 |
Why?
| | Adult | 9 | 2024 | 38394 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2016 | 912 | 0.090 |
Why?
| | Apoptosis | 4 | 2021 | 2559 | 0.090 |
Why?
| | Carcinoma, Papillary | 1 | 2012 | 72 | 0.090 |
Why?
| | Radiopharmaceuticals | 1 | 2012 | 187 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2024 | 1959 | 0.090 |
Why?
| | Vascular Surgical Procedures | 3 | 2004 | 318 | 0.090 |
Why?
| | Young Adult | 3 | 2024 | 13344 | 0.090 |
Why?
| | Cell Line, Tumor | 4 | 2021 | 3408 | 0.090 |
Why?
| | Fluorescent Antibody Technique | 2 | 2002 | 384 | 0.090 |
Why?
| | Patient Care Management | 1 | 2011 | 55 | 0.090 |
Why?
| | Cell Proliferation | 4 | 2021 | 2486 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 188 | 0.080 |
Why?
| | Psychomotor Agitation | 1 | 2011 | 73 | 0.080 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2010 | 74 | 0.080 |
Why?
| | Acute Disease | 2 | 2011 | 1011 | 0.080 |
Why?
| | Extracellular Space | 1 | 2010 | 129 | 0.080 |
Why?
| | Risk Assessment | 4 | 2024 | 3470 | 0.080 |
Why?
| | Calcium | 1 | 2015 | 1187 | 0.080 |
Why?
| | Endotoxins | 1 | 2010 | 220 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 284 | 0.070 |
Why?
| | Interleukin-6 | 2 | 2011 | 786 | 0.070 |
Why?
| | Intestinal Perforation | 1 | 2008 | 46 | 0.070 |
Why?
| | Clinical Trials as Topic | 3 | 2018 | 1036 | 0.070 |
Why?
| | Duodenum | 1 | 2008 | 76 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2015 | 1153 | 0.070 |
Why?
| | Adolescent | 3 | 2024 | 21561 | 0.070 |
Why?
| | Pancreatic Ducts | 1 | 2008 | 79 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 2011 | 4339 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 2008 | 66 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2010 | 366 | 0.070 |
Why?
| | Computer Simulation | 1 | 2011 | 997 | 0.060 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2008 | 230 | 0.060 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 211 | 0.060 |
Why?
| | Mutation | 4 | 2021 | 3999 | 0.060 |
Why?
| | Macrophages | 2 | 2011 | 1545 | 0.060 |
Why?
| | Carotid Arteries | 2 | 2004 | 195 | 0.060 |
Why?
| | Software | 1 | 2011 | 668 | 0.060 |
Why?
| | Hyperplasia | 2 | 2004 | 176 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2706 | 0.060 |
Why?
| | Cell Count | 2 | 2002 | 324 | 0.060 |
Why?
| | Biopsy, Fine-Needle | 2 | 2017 | 68 | 0.060 |
Why?
| | Toll-Like Receptors | 2 | 2002 | 189 | 0.050 |
Why?
| | Coronary Disease | 2 | 2004 | 374 | 0.050 |
Why?
| | Transplantation | 1 | 2004 | 35 | 0.050 |
Why?
| | Time Factors | 5 | 2015 | 6885 | 0.050 |
Why?
| | Vasculitis | 1 | 2004 | 67 | 0.050 |
Why?
| | Insulinoma | 1 | 2003 | 27 | 0.050 |
Why?
| | Signal Transduction | 3 | 2016 | 5094 | 0.050 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2004 | 142 | 0.050 |
Why?
| | Computers | 1 | 2023 | 69 | 0.050 |
Why?
| | Parathyroid Neoplasms | 1 | 2002 | 12 | 0.050 |
Why?
| | Parathyroidectomy | 1 | 2002 | 9 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1380 | 0.050 |
Why?
| | Collateral Circulation | 1 | 2002 | 19 | 0.050 |
Why?
| | Cell Physiological Phenomena | 1 | 2002 | 19 | 0.050 |
Why?
| | Thyrotropin | 1 | 2023 | 116 | 0.050 |
Why?
| | Interleukin-11 | 1 | 2002 | 10 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2004 | 304 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 502 | 0.050 |
Why?
| | Vinblastine | 1 | 2002 | 71 | 0.050 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2002 | 13 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2004 | 203 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2015 | 326 | 0.050 |
Why?
| | Endosonography | 1 | 2003 | 152 | 0.050 |
Why?
| | Receptors, Cytokine | 1 | 2002 | 36 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2015 | 668 | 0.050 |
Why?
| | Risk Factors | 5 | 2012 | 10426 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2002 | 100 | 0.050 |
Why?
| | Lung | 4 | 2002 | 4094 | 0.050 |
Why?
| | Vasopressins | 1 | 2002 | 59 | 0.050 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1734 | 0.050 |
Why?
| | Hemostatics | 1 | 2002 | 55 | 0.040 |
Why?
| | Organ Transplantation | 2 | 2001 | 255 | 0.040 |
Why?
| | Stem Cell Transplantation | 1 | 2002 | 184 | 0.040 |
Why?
| | NF-kappa B | 4 | 2010 | 680 | 0.040 |
Why?
| | Oximes | 1 | 2021 | 24 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2002 | 191 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 227 | 0.040 |
Why?
| | Internship and Residency | 1 | 2011 | 1180 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 68 | 0.040 |
Why?
| | Emergencies | 1 | 2001 | 174 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1094 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2003 | 411 | 0.040 |
Why?
| | Neovascularization, Physiologic | 1 | 2001 | 182 | 0.040 |
Why?
| | Adenoma | 1 | 2002 | 227 | 0.040 |
Why?
| | Interleukins | 1 | 2002 | 251 | 0.040 |
Why?
| | Laparotomy | 1 | 2000 | 112 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2001 | 138 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 371 | 0.040 |
Why?
| | Military Medicine | 1 | 2000 | 67 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2001 | 303 | 0.040 |
Why?
| | Neovascularization, Pathologic | 1 | 2001 | 296 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 769 | 0.040 |
Why?
| | Imidazoles | 1 | 2021 | 240 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 3 | 2010 | 275 | 0.040 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2002 | 449 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 958 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 689 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 197 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 37 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 323 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 3 | 2004 | 43 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2002 | 492 | 0.040 |
Why?
| | Lamin Type B | 1 | 2018 | 7 | 0.040 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 8 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2000 | 272 | 0.040 |
Why?
| | Naphthyridines | 1 | 2018 | 19 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2019 | 251 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 349 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2002 | 966 | 0.040 |
Why?
| | Thyroid Gland | 1 | 2018 | 91 | 0.040 |
Why?
| | Graft Rejection | 1 | 2002 | 577 | 0.040 |
Why?
| | Ventricular Function, Left | 1 | 2001 | 503 | 0.040 |
Why?
| | Homeostasis | 1 | 2002 | 617 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 875 | 0.030 |
Why?
| | Immunoblotting | 1 | 2018 | 310 | 0.030 |
Why?
| | Aged, 80 and over | 4 | 2016 | 7699 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2002 | 349 | 0.030 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 17 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 349 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 171 | 0.030 |
Why?
| | Frozen Sections | 1 | 1996 | 25 | 0.030 |
Why?
| | Hemorrhage | 1 | 2001 | 732 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2000 | 977 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2015 | 3585 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2002 | 828 | 0.030 |
Why?
| | Laparoscopy | 1 | 2000 | 453 | 0.030 |
Why?
| | Cardiac Surgical Procedures | 1 | 2002 | 576 | 0.030 |
Why?
| | Cricoid Cartilage | 1 | 2015 | 17 | 0.030 |
Why?
| | Varicella Zoster Virus Infection | 1 | 2016 | 24 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 803 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 97 | 0.030 |
Why?
| | Tracheostomy | 1 | 1997 | 134 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 89 | 0.030 |
Why?
| | Prospective Studies | 3 | 2015 | 7660 | 0.030 |
Why?
| | Taxoids | 1 | 2015 | 101 | 0.030 |
Why?
| | Carboplatin | 1 | 2015 | 146 | 0.030 |
Why?
| | Herpes Simplex | 1 | 2016 | 95 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2015 | 30 | 0.030 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 81 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 971 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 623 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2015 | 167 | 0.030 |
Why?
| | Lung Diseases | 1 | 2001 | 783 | 0.030 |
Why?
| | Disease Progression | 1 | 2002 | 2741 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2865 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2015 | 225 | 0.030 |
Why?
| | Anilides | 1 | 2014 | 71 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 137 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 839 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 617 | 0.030 |
Why?
| | Paclitaxel | 1 | 2015 | 237 | 0.030 |
Why?
| | Niacinamide | 1 | 2014 | 82 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2014 | 95 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 308 | 0.030 |
Why?
| | Doxorubicin | 1 | 2015 | 352 | 0.030 |
Why?
| | Radioactive Tracers | 1 | 2013 | 4 | 0.030 |
Why?
| | Melatonin | 1 | 2014 | 155 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1497 | 0.020 |
Why?
| | Mice, Inbred Strains | 2 | 2004 | 411 | 0.020 |
Why?
| | Cell Movement | 3 | 2001 | 972 | 0.020 |
Why?
| | Incidence | 2 | 2011 | 2836 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1049 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2014 | 272 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 417 | 0.020 |
Why?
| | Postoperative Care | 1 | 2014 | 274 | 0.020 |
Why?
| | Preoperative Period | 1 | 2012 | 142 | 0.020 |
Why?
| | Serotonin | 1 | 2014 | 322 | 0.020 |
Why?
| | Inflammation | 1 | 2003 | 2858 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1103 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 983 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 498 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 326 | 0.020 |
Why?
| | Intraoperative Period | 2 | 2003 | 67 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 101 | 0.020 |
Why?
| | Linear Models | 1 | 2012 | 856 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2010 | 56 | 0.020 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 269 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2002 | 2057 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 856 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3002 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1947 | 0.020 |
Why?
| | Workload | 1 | 2011 | 163 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2012 | 495 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2011 | 221 | 0.020 |
Why?
| | Safety | 1 | 2011 | 346 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1498 | 0.020 |
Why?
| | Rupture | 1 | 2008 | 89 | 0.020 |
Why?
| | Bile Ducts | 1 | 2008 | 68 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1101 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2014 | 871 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1320 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1145 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1197 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 321 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1313 | 0.020 |
Why?
| | Cattle | 1 | 2010 | 997 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2089 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 525 | 0.020 |
Why?
| | Patient Readmission | 1 | 2012 | 706 | 0.020 |
Why?
| | Neoplasms | 1 | 2002 | 2703 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3160 | 0.020 |
Why?
| | Patient Care Team | 1 | 2011 | 642 | 0.010 |
Why?
| | Growth Substances | 1 | 2004 | 148 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 1935 | 0.010 |
Why?
| | Protein Binding | 1 | 2010 | 2237 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3276 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1449 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3317 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2003 | 83 | 0.010 |
Why?
| | Monokines | 1 | 2002 | 22 | 0.010 |
Why?
| | Chemokine CXCL2 | 1 | 2002 | 42 | 0.010 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2002 | 87 | 0.010 |
Why?
| | Transcription Factor RelA | 1 | 2002 | 85 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2002 | 270 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2001 | 80 | 0.010 |
Why?
| | Peroxidase | 1 | 2002 | 183 | 0.010 |
Why?
| | Endothelial Growth Factors | 1 | 2001 | 65 | 0.010 |
Why?
| | Lymphokines | 1 | 2001 | 133 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2002 | 117 | 0.010 |
Why?
| | Wounds, Nonpenetrating | 1 | 2004 | 289 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 161 | 0.010 |
Why?
| | Interleukin-8 | 1 | 2002 | 271 | 0.010 |
Why?
| | United States | 1 | 2018 | 15065 | 0.010 |
Why?
| | Postoperative Period | 1 | 2002 | 358 | 0.010 |
Why?
| | Surgery, Plastic | 1 | 2001 | 46 | 0.010 |
Why?
| | Protein Transport | 1 | 2002 | 441 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 794 | 0.010 |
Why?
| | Cohort Studies | 1 | 2011 | 5736 | 0.010 |
Why?
| | Trachea | 1 | 2002 | 255 | 0.010 |
Why?
| | Aorta | 1 | 2002 | 415 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2002 | 648 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 410 | 0.010 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2002 | 270 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2001 | 551 | 0.010 |
Why?
| | Colorado | 1 | 2008 | 4532 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2011 | 5892 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2051 | 0.010 |
Why?
| | Escherichia coli | 1 | 2002 | 829 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1996 | 176 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1494 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 222 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 1996 | 192 | 0.010 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 1997 | 176 | 0.010 |
Why?
| | Coronary Artery Disease | 1 | 2001 | 701 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2002 | 4182 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2002 | 2822 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1996 | 605 | 0.010 |
Why?
|
|
Raeburn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|